Alvotech

66 articles with Alvotech

• Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia

  1/24/2023

  Alvotech and Bioventure, a wholly owned subsidiary of GlobalOne Healthcare Holding LLC, the healthcare division of Yas Holding LLC, announced that the Saudi Food & Drug Authority has approved the manufacturing and distribution of AVT02, a biosimilar for Humira®, which is commonly indicated for the treatment of rheumatoid arthritis and several other inflammatory diseases.

• Alvotech Completes $137 Million Private Share Placement

  1/23/2023

  Alvotech announced the completion of a private placement of approximately $137 million, at current exchange rates, of its ordinary shares, par value $0.01 per share, at a purchase price of $11.57 per Share at current exchange rates.

• Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate

  1/13/2023

  Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Japanese pharmaceutical company Fuji Pharma Co., Ltd. have decided to expand their existing exclusive commercialization partnership covering Japan, by adding a new undisclosed biosimilar candidate.

• Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®

  1/11/2023

  Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced the initiation of a pharmacokinetic study for AVT05, a biosimilar candidate to Simponi® and Simponi Aria®.

• Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

  1/6/2023

  Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the U.S. Food and Drug Administration has accepted for review a Biologics License Application for AVT04, Alvotech’s proposed biosimilar to Stelara®, which is prescribed to treat a variety of inflammatory conditions.

• Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®

  12/22/2022

  Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced that the FDA has granted a new Biosimilar User Fee Amendment goal date of April 13, 2023, for Alvotech’s original Biologics License Application for AVT02 as biosimilar to Humira®.

• Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT to headline field

  12/16/2022

  Reference is made to the announcement issued earlier today about the completion of a private placement of subordinated convertible bonds.

• Alvotech Completes $59.7 Million Private Placement

  12/16/2022

  Alvotech announced completion of a private placement of approximately US$59.7 million, at current exchange rates, of subordinated convertible bonds, convertible into new fully paid ordinary shares of Alvotech.

• Alvotech Shares Start Trading on Nasdaq Iceland Main Market

  12/8/2022

  Alvotech announced that trading in its shares will move from the Nasdaq Iceland First North Growth market to the Nasdaq Iceland Main Market, starting December 8, 2022.

• Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe

  12/7/2022

  Alvotech and STADA are contributing to the availability of high-quality biologic treatments in Europe by rolling out their Hukyndra high-concentration, low-volume, citrate-free formulation of adalimumab in several European countries.

• Alvotech Announces Changes to its Leadership Team

  12/1/2022

  Hafrun Fridriksdottir, previously Executive VP and Head of Global R&D at Teva, will become Chief Operating Officer.

• Alvotech Secures Financing Facilities of Approximately $136 Million

  11/16/2022

  Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced financing facilities securing gross proceeds of approximately $136 million, at current exchange rates.

• Alvotech Reports Financial Results for First Nine Months of 2022 And Provides Business Update

  11/16/2022

  Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, reported unaudited financial results for the first nine months of 2022 and provided a summary of recent corporate highlights.

• Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira®

  11/14/2022

  Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide announced that the Therapeutic Goods Administration of Australia has granted marketing authorization to Cipla Australia Pty Ltd for Alvotech’s AVT02, a high-concentration low-volume biosimilar to Humira®.

• Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology Conference

  11/10/2022

  Alvotech announced that it will present two posters and will be featured in an Ignite Talk related to its switching study for ATV02 at the American College of Rheumatology Convergence Conference, being held in Philadelphia on November 10-14, 2022.

• Alvotech to Report First Nine Months Financial Results on November 15, 2022 and Host Business Update Conference Call at 8:00 am ET on November 16, 2022

  10/27/2022

  Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first nine months of 2022, after U.S. markets close on Tuesday, November 15, 2022.

• Alvotech to Participate in Upcoming Jefferies London Healthcare Conference in November

  10/26/2022

  Alvotech (NASDAQ: ALVO), a global biotech specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of the leadership team will participate in the Jefferies London Healthcare Conference from November 15th to November 17th.

• Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care

  10/19/2022

  Alvotech and the JAMP Pharma Group announced that the companies have expanded their exclusive partnership to commercialize biosimilars developed and manufactured by Alvotech, by adding two biosimilar candidates from Alvotech’s pipeline: AVT16 a biosimilar for an immunology product and AVT33, a biosimilar for an oncology product.

• Alvotech’s Partner Submits Application for Marketing Approval of First Biosimilar Candidate in Japan

  10/17/2022

  Alvotech announced that its commercialization partner Fuji Pharma Co., Ltd. has submitted an application to the Japanese Ministry of Health, Labor and Welfare for marketing approval of the first biosimilar candidate developed under the companies’ exclusive commercialization partnership.

• Alvotech Appoints Sarah Tanksley as Chief Quality Officer

  10/11/2022

  Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Sarah Tanksley will join its corporate leadership team as Chief Quality Officer, effective October 14.